Thomas Tillett – Cofounder and CEO of MBF Therapeutics, a life science company, is developing innovative gene-based check point inhibitor and immunomodulating immunotherapies to treat cancer and infectious diseases in both animals and humans. Tom is the founder and Executive Director of Sustained Acts, a non-profit organisation, and serves on the Friends of Kijabe Hospital Board of Directors. He was founder, and CEO of RHeoGene where he and his team created the RheoSwitch® Therapeutic System (RTS) that led to the first human clinical trial of a small molecule-induced gene regulation system.
In 2007, Thomas successfully completed the merger of RheoGene Inc. with Intrexon Corporation who has continued the development of RTS through a various clinical trial for cancer and other important therapeutic indications. In April 2019, the FDA announced that the RheoSwitch Therapeutic System for glioma blastoma was approved for Fast Track designation.